© 2018 Innate Repair

All rights reserved

Targeting therapy-resistant cancer cells

Through novel biology concepts


What we do

Current anti-cancer treatments can be quite effective at killing certain types of cancer cell within a tumor. As a result, the tumor shrinks. Unfortunately, they are not effective at killing other, more specialized types of cancer cell within the tumor. Therefore, it is difficult to make a tumor disappear completely. So long as cancer cells remain, it might come back.


Because some of the cancer cells that evade therapy can regenerate the tumor, we sometimes refer to them as Cancer Stem Cells.


Innate Repair scientists discovered a new molecular mechanism that regulates the Cancer Stem Cells. They utilized it as a blueprint to identify treatments that can kill these elusive cancer cells. Now, Innate Repair is focusing on the complete validation of these treatments, in order to bring them to the patient, as new weapons against the disease.


In addition, Innate Repair has identified biomarkers that can help with patient diagnosis/prognosis, and optimal patient selection for these treatments. We also developed a new method that helps us identify treatments that target Cancer Stem Cells.


Innate Repair is a spinoff venture from the Technische Universitaet Dresden, a center of Excellence in Germany. It is a registered company in London, UK.


Startup Award: Innate Repair receives the

Top 20 Startup Lighthouse Award

- In Madrid, Spain

Top 20 Awards Logo.png

Latest Publication: Innate Repair identifies molecular mechanism that cancer cells use to evade therapy

- And ways to block it


Press Release: Killing the unkillable cancer cells

- A simple account of our latest work


Our Research

Innate Repair's core team includes University Professors, both basic scientists and physicians, with many years of research and clinical experience as well as Company Builders with years of Executive experience. We have close collaborators and Advisors in the EU, USA, and Israel, bringing us in direct contact with many Industry and University partners.

We have published our core concepts in top international journals such as Nature, PNAS, Diabetes, etc. Through Innate Repair we will ensure implementation of our findings, providing cancer patients with new therapeutic options.

You can read more about our molecular discoveries on Wikipedia by clicking the image.


The Team

Our Founding Team

Andreas Androutsellis-Theotokis

  • Grey LinkedIn Icon

Andreas is the chief scientist and inventor at Innate Repair. He studied at Imperial College, London (BSc, PhD) and performed research at Yale and the NIH. He has run his own labs at the TU-Dresden (Group Leader) and the University of Nottingham (Assoc. Prof.).


The TU Dresden is a public research university. It ranks among the best universities of engineering and technology in Germany. It is a member of TU9, a consortium of the nine leading German Institutes of Technology and one of eleven German universities with the title "University of Excellence".

Stefan R. Bornstein

  • Grey LinkedIn Icon

Stefan is the Director of the Centre for Internal Medicine and the Medical Clinic and Policlinic III at the University Hospital Carl Gustav Carus of the Technical University of Dresden as well as the medical faculty’s Vice Dean of International Affairs and Development and a member of the supervisory board of the University Hospital of Dresden. Furthermore, he is Chair and Honorary Consultant for Diabetes and Endocrinology at King's College London.


Our Network of Advisors

Andrew V. Schally

  • Grey LinkedIn Icon

Andrew is an Endocrine Oncologist and Distinguished Medical Research Scientist of the US Veteran Affairs Department, as well as Professor of Pathology, Professor of Medicine, Division of Oncology, and Endocrinology at the University of Miami. He is a recipient of the Nobel prize in Physiology or Medicine.

George P. Chrousos

  • Grey LinkedIn Icon

George is Professor of Pediatrics and Endocrinology, Chairman, First Dept. of Pediatrics, National and Kapodistrian University of Athens. He holds a UNESCO Chair, has received numerous international awards and is a member of the US National Academy of Medicine (Institute of Medicine).

Ronen Leker

  • Grey LinkedIn Icon

Professor Ronen R. Leker MD, FAHA is the Director of the Stroke Unit, Stroke Center and the Peritz and Chantal Sheinberg Cerebrovascular Research Laboratory and Jacob L. Sebulsky Chair in Neurology, Department of Neurology, at the Hadassah-Hebrew University Medical Center

Lila Koumandou

  • Grey LinkedIn Icon

Lila holds a BSc in Biology from MIT and a PhD in Biochemistry from the University of Cambridge, where she also worked as a postdoc. She returned to Greece on a Marie Curie Fellowship, and is currently a Lecturer at the Department of Biotechnology of the Agricultural University of Athens.

Stephanos Androutsellis-Theotokis

  • Grey LinkedIn Icon

Stephanos holds a B.Eng from Imperial College London, an MSc from Johns Hopkins, and a PhD from the Athens U. of Economics and Business. He teaches IT courses at the hauniv.edu. He is a software developer and has cofounded several startups including als.gr and phenometry.com.

Nadine Schmieder-Galfe

  • Grey LinkedIn Icon

Nadine is an expert in technology transfer. She trains international life science researchers and gives workshops worldwide on technology transfer-relevant topics, including intellectual property (patents, trademarks, etc.), business modelling, entrepreneurship, as well as funding and venture capital investments. She is a trained biotechnologist with an additional MBA in the field of economics and law. Together with a team from Technische Universität Dresden, she has founded her first spin-off ZELLMECHANIK DRESDEN GmbH in 2015, and has recently been awarded with the 2017 Saxon Female Entrepreneur of the Year Award.

Deric M. Park

  • Grey LinkedIn Icon

Deric M. Park, MD, FACP is Associate Professor of Neurology at the University of Chicago, Director of Medical Neuro-Oncology, and a faculty member of the Committee on Clinical Pharmacology and Pharmacogenomics.  He is committed to identifying more effective therapies for patients suffering from brain-spine tumors.

Steven W. Poser

  • Grey LinkedIn Icon

Steven received his Ph.D. from the University of Washington in Neurobiology. In both industry and academic laboratories, he successfully designed and implemented signal transduction and cell characterization studies in cancer, stem cell, and primary neuronal culture systems. These became an integral part of cell-based product development and drug discovery programs as well as resulted in numerous publications.

Selected Publications

01 Nature.png

Journal: Nature

Year: 2006

Significance: Neural stem cells operate the newly discovered Hes3 signaling pathway. Activation of this pathway leads to functional recovery in models of ischemic stroke.

02 CSH.png

Journal: Cold Spring Harbor Symposia on Quantitative Biology

Year: 2008

Significance: Activation of the the Hes3 pathway by insulin in models of Parkinson's disease promotes functional recovery.

03 PNAS.png

Journal: Proceedings of the National Academy of Sciences

Year: 2009

Significance: Activation of the the Hes3 pathway in a manner that protects unwanted effects on blood vessels in models of Parkinson's disease promotes functional recovery.

04 SciRep GBM.png

Journal: Scientific Reports

Year: 2013

Significance: The Hes3 pathway controls cultured cancer stem cells from different patients. Blocking the pathway by RNA interference (target: Hes3) kills those cells.

05 JBC.png

Journal: Journal of Biological Chemistry

Year: 2014

Significance: The Hes3 pathway protects pancreatic islet cells during injury and regulates insulin production with powerful consequences in models of type 1 diabetes.

06 Diabetes.png

Journal: Diabetes

Year: 2016

Significance: The Hes3 pathway promotes pancreatic regeneration after injury with powerful consequences in models of type 1 diabetes.

07 SciRep Xenia.png

Journal: Scientific Reports

Year: 2018

Significance: Pancreatic damage, high fat diet, and metformin administration regulate the Hes3 pathway in the brain, providing a new molecular mechanism by which metabolic dysfunction affects the brain.

FASEB title page 2.png

Journal: FASEB J

Year: 2019

Significance: Some cells in aggressive brain cancers can evade current therapies by switching from the standard molecular mechanisms that regulate their growth and survival to an alternative one. In this way, they become resistant to therapies that target the standard molecular mechanism. Knowing this ability allowed us to define the alternative mechanism and to identify treatments that target the cells that use it. Simply put, we discovered an escape route that cancer cells use to evade therapy and then we found drugs that block it.


Contact Us

Innate Repair is registered in London, UK.


Temporary contact information:

Technische Universität Dresden (TUD) / University Hospital Carl Gustav Carus Dresden (UKD)

Medizinische Klinik und Poliklinik III (MK3),

Fetscherstrasse 74

Dresden 01307